Baxter International Inc (BAX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Baxter International Inc stock (BAX) is currently trading at $17.12. Baxter International Inc PS ratio (Price-to-Sales) is 0.77. Analyst consensus price target for BAX is $21.96. WallStSmart rates BAX as Underperform.
- BAX PE ratio analysis and historical PE chart
- BAX PS ratio (Price-to-Sales) history and trend
- BAX intrinsic value — DCF, Graham Number, EPV models
- BAX stock price prediction 2025 2026 2027 2028 2029 2030
- BAX fair value vs current price
- BAX insider transactions and insider buying
- Is BAX undervalued or overvalued?
- Baxter International Inc financial analysis — revenue, earnings, cash flow
- BAX Piotroski F-Score and Altman Z-Score
- BAX analyst price target and Smart Rating
Baxter International Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Baxter International Inc (BAX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around peg ratio and return on equity. Fundamentals are solid but monitor weak areas for improvement.
Baxter International Inc (BAX) Key Strengths (5)
Paying less than $1 for every $1 of annual revenue
Earnings per share surging 237.90% year-over-year
109.98% of shares held by major funds and institutions
Trading at 1.36x book value, attractively priced
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Baxter International Inc (BAX) Areas to Watch (5)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Very thin margins with limited operational efficiency
Modest revenue growth at 8.00%
Baxter International Inc (BAX) Detailed Analysis Report
Overall Assessment
This company scores 53/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, EPS Growth, Institutional Own.. Valuation metrics including Price/Sales (0.77), Price/Book (1.36) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 237.90%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, PEG Ratio. Some valuation metrics including PEG Ratio (36.68) suggest expensive pricing. Growth concerns include Revenue Growth at 8.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -13.70%, Operating Margin at 7.36%, Profit Margin at -8.51%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -13.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Sales, EPS Growth) and negatives (Return on Equity, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BAX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BAX's Price-to-Sales ratio of 0.77x trades at a deep discount to its historical average of 2.68x (1th percentile). The current valuation is 80% below its historical high of 3.83x set in Sep 2018, and 3% above its historical low of 0.74x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Baxter International Inc (BAX) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Baxter International Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 11.2B with 8% growth year-over-year. The company is currently unprofitable, posting a -8.5% profit margin.
Key Findings
Generating 444M in free cash flow and 584M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -8.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Dividend sustainability with a current yield of 3.1%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 9.8B is significantly higher than cash (2.0B). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Baxter International Inc.
Bottom Line
Baxter International Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Baxter International Inc(BAX)
NYSE
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.